Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review

Prostate Cancer and Prostatic Diseases volume 17, pages 220–226 (2014)Cite this article

Subjects

Abstract

Objectives:

Neuroendocrine prostate cancers (NEPCs) are rare. The current lack of consensus for clinical, biological and pathological characterization as well as therapeutic approach makes the management of those tumors a clinical challenge. This literature review aims to summarize available data on the characterization and management of patients with prostate cancer with a neuroendocrine element. We try to identify major controversies and uncertainties in order to understand all aspects of this particular entity.

Methods:

We searched for all articles published and registered in the MEDLINE database before 31 November 2013 with the following search terms: ((‘prostatic neoplasms’ (MeSH Terms)) AND (‘carcinoma, neuroendocrine’ (MeSH Terms)) OR (‘carcinoma, small cell’ (MeSH Terms))) AND (English (Language)).

Results:

Case reports, letters or comments were excluded. We then selected relevant articles from titles and abstracts. Overall, 278 articles published between 1976 and November 2013 were identified. No definition of NEPC seems to be clearly established. Natural history of the disease reveals poor prognosis with median survival of up to 10 to 13 months. Histological characterization appears difficult. Serum markers could be helpful with some controversies in terms of prognostic significance. Concerning management, the majority of patients received local treatment combined with chemotherapy in case of early and localized disease. Few clinical trials described strategy for metastatic disease.

Conclusions:

The exploration of the different pathways implicated in the neuroendocrine differentiation of prostate cancers is essential for the comprehension of castration-resistance mechanisms. It will enable the identification of optimal therapeutic strategies for which no recommendation is currently established. Inclusion in prospective clinical trials appears necessary to identify the adequate strategy.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. di Sant'Agnese PA, Cockett AT . Neuroendocrine differentiation in prostatic malignancy. Cancer 1996; 78: 357–361.

    Article  CAS  PubMed  Google Scholar 

  2. Helpap B, Kollermann J . Undifferentiated carcinoma of the prostate with small cell features: immunohistochemical subtyping and reflections on histogenesis. Virchows Arch 1999; 434: 385–391.

    Article  CAS  PubMed  Google Scholar 

  3. Abrahamsson PA . Neuroendocrine differentiation in prostatic carcinoma. Prostate 1999; 39: 135–148.

    Article  CAS  PubMed  Google Scholar 

  4. Berruti A, Dogliotti L, Mosca A, Bellina M, Mari M, Torta M et al. Circulating neuroendocrine markers in patients with prostate carcinoma. Cancer 2000; 88: 2590–2597.

    Article  CAS  PubMed  Google Scholar 

  5. Abbas F, Civantos F, Benedetto P, Soloway MS . Small cell carcinoma of the bladder and prostate. Urology 1995; 46: 617–630.

    Article  CAS  PubMed  Google Scholar 

  6. Grobholz R, Griebe M, Sauer CG, Michel MS, Trojan L, Bleyl U . Influence of neuroendocrine tumor cells on proliferation in prostatic carcinoma. Hum Pathol 2005; 36: 562–570.

    Article  CAS  PubMed  Google Scholar 

  7. Sciarra A, Innocenzi M, Ravaziol M, Minisola F, Alfarone A, Cattarino S et al. [Role of neuroendocrine cells in prostate cancer progression]. Urologia 2011; 78: 126–131.

    Article  PubMed  Google Scholar 

  8. Vashchenko N, Abrahamsson PA . Neuroendocrine differentiation in prostate cancer: implications for new treatment modalities. Eur Urol 2005; 47: 147–155.

    Article  CAS  PubMed  Google Scholar 

  9. Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH . Chemotherapy for small cell carcinoma of prostatic origin. J Urol 1992; 147: 935–937.

    Article  CAS  PubMed  Google Scholar 

  10. di Sant'Agnese PA . Neuroendocrine differentiation in prostatic carcinoma: an update on recent developments. Ann Oncol 2001; 12 (Suppl 2): S135–S140.

    Article  PubMed  Google Scholar 

  11. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE et al. Treatment outcomes of small cell carcinoma of the prostate: a single-center study. Cancer 2007; 110: 1729–1737.

    Article  PubMed  Google Scholar 

  12. Leibovici D, Spiess PE, Agarwal PK, Tu SM, Pettaway CA, Hitzhusen K et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007; 109: 198–204.

    Article  PubMed  Google Scholar 

  13. Nishio R, Furuya Y, Nagakawa O, Fuse H . Metastatic prostate cancer with normal level of serum prostate-specific antigen. Int Urol Nephrol 2003; 35: 189–192.

    Article  CAS  PubMed  Google Scholar 

  14. Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol 2002; 20: 3072–3080.

    Article  CAS  PubMed  Google Scholar 

  15. Galanis E, Frytak S, Lloyd RV . Extrapulmonary small cell carcinoma. Cancer 1997; 79: 1729–1736.

    Article  CAS  PubMed  Google Scholar 

  16. Spieth ME, Lin YG, Nguyen TT . Diagnosing and treating small-cell carcinomas of prostatic origin. Clin Nucl Med 2002; 27: 11–17.

    Article  PubMed  Google Scholar 

  17. Kawai S, Hiroshima K, Tsukamoto Y, Tobe T, Suzuki H, Ito H et al. Small cell carcinoma of the prostate expressing prostate-specific antigen and showing syndrome of inappropriate secretion of antidiuretic hormone: an autopsy case report. Pathol Int 2003; 53: 892–896.

    Article  PubMed  Google Scholar 

  18. Palmgren JS, Karavadia SS, Wakefield MR . Unusual and underappreciated: small cell carcinoma of the prostate. Semin Oncol 2007; 34: 22–29.

    Article  CAS  PubMed  Google Scholar 

  19. Tu SM, Lin SH, Logothetis CJ . Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol 2002; 3: 508–513.

    Article  CAS  PubMed  Google Scholar 

  20. Ishida E, Nakamura M, Shimada K, Tasaki M, Konishi N . Immunohistochemical analysis of neuroendocrine differentiation in prostate cancer. Pathobiology 2009; 76: 30–38.

    Article  CAS  PubMed  Google Scholar 

  21. Lotan TL, Gupta NS, Wang W, Toubaji A, Haffner MC, Chaux A et al. ERG gene rearrangements are common in prostatic small cell carcinomas. Mod Pathol 2011; 24: 820–828.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Beltran H, Tagawa ST, Park K, MacDonald T, Milowsky MI, Mosquera JM et al. Challenges in recognizing treatment-related neuroendocrine prostate cancer. J Clin Oncol 2012; 30: e386–e389.

    Article  PubMed  Google Scholar 

  23. Furtado P, Lima MV, Nogueira C, Franco M, Tavora F . Review of small cell carcinomas of the prostate. Prostate Cancer 2011; 2011: 543272.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Nelson EC, Cambio AJ, Yang JC, Ok JH, Lara PN Jr., Evans CP . Clinical implications of neuroendocrine differentiation in prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 6–14.

    Article  CAS  PubMed  Google Scholar 

  25. Dunning NL, Laversin SA, Miles AK, Rees RC . Immunotherapy of prostate cancer: should we be targeting stem cells and EMT? Cancer Immunol Immunother 2011; 60: 1181–1193.

    Article  CAS  PubMed  Google Scholar 

  26. Smith BN, Odero-Marah VA . The role of Snail in prostate cancer. Cell Adh Migr 2012; 6: 433–441.

    Article  PubMed  PubMed Central  Google Scholar 

  27. McKeithen D, Graham T, Chung LW, Odero-Marah V . Snail transcription factor regulates neuroendocrine differentiation in LNCaP prostate cancer cells. Prostate 2010; 70: 982–992.

    CAS  PubMed  PubMed Central  Google Scholar 

  28. Chu GC, Zhau HE, Wang R, Rogatko A, Feng X, Zayzafoon M et al. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization. Endocr Relat Cancer 2014; 21: 311–326.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Alberti C . Neuroendocrine differentiation in prostate carcinoma: focusing on its pathophysiologic mechanisms and pathological features. G Chir 2010; 31: 568–574.

    CAS  PubMed  Google Scholar 

  30. Sagnak L, Topaloglu H, Ozok U, Ersoy H . Prognostic significance of neuroendocrine differentiation in prostate adenocarcinoma. Clin Genitourin Cancer 2011; 9: 73–80.

    Article  PubMed  Google Scholar 

  31. Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR . Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol 2006; 30: 684–693.

    Article  PubMed  Google Scholar 

  32. Wang W, Epstein JI . Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol 2008; 32: 65–71.

    Article  PubMed  Google Scholar 

  33. Mai KT, Roustan Delatour NL, Assiri A, Al-Maghrabi H . Secondary prostatic adenocarcinoma: a cytopathological study of 50 cases. Diagn Cytopathol 2007; 35: 91–95.

    Article  PubMed  Google Scholar 

  34. Jongsma J, Oomen MH, Noordzij MA, Romijn JC, van der Kwast TH, Schroder FH et al. Androgen-independent growth is induced by neuropeptides in human prostate cancer cell lines. Prostate 2000; 42: 34–44.

    Article  CAS  PubMed  Google Scholar 

  35. Stein ME, Bernstein Z, Abacioglu U, Sengoz M, Miller RC, Meirovitz A et al. Small cell (neuroendocrine) carcinoma of the prostate: etiology, diagnosis, prognosis, and therapeutic implications–a retrospective study of 30 patients from the rare cancer network. Am J Med Sci 2008; 336: 478–488.

    Article  PubMed  Google Scholar 

  36. Palapattu GS, Wu C, Silvers CR, Martin HB, Williams K, Salamone L et al. Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer. Prostate 2009; 69: 787–798.

    Article  CAS  PubMed  Google Scholar 

  37. Ather MH, Abbas F, Faruqui N, Israr M, Pervez S . Correlation of three immunohistochemically detected markers of neuroendocrine differentiation with clinical predictors of disease progression in prostate cancer. BMC Urol 2008; 8: 21.

    Article  PubMed  PubMed Central  Google Scholar 

  38. Fernandes RC, Matsushita MM, Mauad T, Nascimento Saldiva PH . Prostate carcinoma with neuroendocrine differentiation: case report and literature review. Rev Hosp Clin Fac Med Sao Paulo 2001; 56: 153–158.

    Article  CAS  PubMed  Google Scholar 

  39. Tamas EF, Epstein JI . Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate. Am J Surg Pathol 2006; 30: 980–985.

    Article  PubMed  Google Scholar 

  40. Jeetle SS, Fisher G, Yang ZH, Stankiewicz E, Moller H, Cooper CS et al. Neuroendocrine differentiation does not have independent prognostic value in conservatively treated prostate cancer. Virchows Arch 2012; 461: 103–107.

    Article  CAS  PubMed  Google Scholar 

  41. Kamiya N, Akakura K, Suzuki H, Isshiki S, Komiya A, Ueda T et al. Pretreatment serum level of neuron specific enolase (NSE) as a prognostic factor in metastatic prostate cancer patients treated with endocrine therapy. Eur Urol 2003; 44: 309–314.

    Article  PubMed  Google Scholar 

  42. Aoki H, Ishidoya S, Ito A, Endoh M, Shimazui T, Arai Y . Experience of the treatment with gemcitabine, docetaxel, and carboplatin (GDC) chemotherapy for patients with small-cell carcinoma of the prostate. Int J Urol 2006; 13: 1254–1258.

    Article  PubMed  Google Scholar 

  43. May M, Siegsmund M, Hammermann F, Loy V, Gunia S . Prognostic significance of proliferation activity and neuroendocrine differentiation to predict treatment failure after radical prostatectomy. Scand J Urol Nephrol 2007; 41: 375–381.

    Article  CAS  PubMed  Google Scholar 

  44. Gunia S, Albrecht K, Koch S, Herrmann T, Ecke T, Loy V et al. Ki67 staining index and neuroendocrine differentiation aggravate adverse prognostic parameters in prostate cancer and are characterized by negligible inter-observer variability. World J Urol 2008; 26: 243–250.

    Article  PubMed  Google Scholar 

  45. Autorino R, Lamendola MG, De LG, De SM, Giuliano F, D' Armiento M et al. Neuroendocrine immunophenotype as predictor of clinical recurrence in 110 patients with prostate cancer. Int J Immunopathol Pharmacol 2007; 20: 765–770.

    Article  CAS  PubMed  Google Scholar 

  46. Krauss DJ, Hayek S, Amin M, Ye H, Kestin LL, Zadora S et al. Prognostic significance of neuroendocrine differentiation in patients with Gleason score 8-10 prostate cancer treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 2011; 81: e119–e125.

    Article  PubMed  Google Scholar 

  47. Lilleby W, Paus E, Skovlund E, Fossa SD . Prognostic value of neuroendocrine serum markers and PSA in irradiated patients with pN0 localized prostate cancer. Prostate 2001; 46: 126–133.

    Article  CAS  PubMed  Google Scholar 

  48. Mackey JR, Au HJ, Hugh J, Venner P . Genitourinary small cell carcinoma: determination of clinical and therapeutic factors associated with survival. J Urol 1998; 159: 1624–1629.

    Article  CAS  PubMed  Google Scholar 

  49. Asmis TR, Reaume MN, Dahrouge S, Malone S . Genitourinary small cell carcinoma: a retrospective review of treatment and survival patterns at The Ottawa Hospital Regional Cancer Center. BJU Int 2006; 97: 711–715.

    Article  PubMed  Google Scholar 

  50. Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol 2011; 22: 2476–2481.

    Article  CAS  PubMed  Google Scholar 

  51. Culine S, El DM, Lamy PJ, Iborra F, Avances C, Pinguet F . Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol 2007; 178: 844–848.

    Article  CAS  PubMed  Google Scholar 

  52. Loriot Y, Massard C, Gross-Goupil M, Di PM, Escudier B, Bossi A et al. Combining carboplatin and etoposide in docetaxel-pretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features. Ann Oncol 2009; 20: 703–708.

    Article  CAS  PubMed  Google Scholar 

  53. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 2013; 19: 3621–3630.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Aparicio A, Tzelepi V, Araujo JC, Guo CC, Liang S, Troncoso P et al. Neuroendocrine prostate cancer xenografts with large-cell and small-cell features derived from a single patient’s tumor: morphological, immunohistochemical, and gene expression profiles. Prostate 2011; 71: 846–856.

    Article  CAS  PubMed  Google Scholar 

  55. Ueda T, Suzuki H, Akakura K, Ishihara M, Kamiya N, Komiya A et al. Bisphosphonate and low-dose dexamethasone treatment for patients with hormone-refractory prostate cancer. Hinyokika Kiyo 2006; 52: 515–521.

    PubMed  Google Scholar 

  56. Hsieh TC, Lin CY, Lin HY, Wu JM . AKT/mTOR as novel targets of polyphenol piceatannol possibly contributing to inhibition of proliferation of cultured prostate cancer cells. ISRN Urol 2012; 2012: 272697.

    PubMed  PubMed Central  Google Scholar 

  57. Ciarlo M, Benelli R, Barbieri O, Minghelli S, Barboro P, Balbi C et al. Regulation of neuroendocrine differentiation by AKT/hnRNPK/AR/beta-catenin signaling in prostate cancer cells. Int J Cancer 2012; 131: 582–590.

    Article  CAS  PubMed  Google Scholar 

  58. Beltran H, Rickman DS, Park K, Chae SS, Sboner A, MacDonald TY et al. Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. Cancer Discov 2011; 1: 487–495.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Meulenbeld HJ, Bleuse JP, Vinci EM, Raymond E, Vitali G, Santoro A et al. Randomized phase II study of danusertib in patients with metastatic castration-resistant prostate cancer after docetaxel failure. BJU Int 2013; 111: 44–52.

    Article  CAS  PubMed  Google Scholar 

  60. Veltri RW, Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E et al. Long-term assessment of prostate cancer progression free survival: evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. Prostate 2008; 68: 1806–1815.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Gong J, Lee J, Akio H, Schlegel PN, Shen R . Attenuation of apoptosis by chromogranin A-induced Akt and survivin pathways in prostate cancer cells. Endocrinology 2007; 148: 4489–4499.

    Article  CAS  PubMed  Google Scholar 

  62. Feng S, Agoulnik IU, Truong A, Li Z, Creighton CJ, Kaftanovskaya EM et al. Suppression of relaxin receptor RXFP1 decreases prostate cancer growth and metastasis. Endocr Relat Cancer 2010; 17: 1021–1033.

    Article  CAS  PubMed  Google Scholar 

  63. Littlepage LE, Sternlicht MD, Rougier N, Phillips J, Gallo E, Yu Y et al. Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res 2010; 70: 2224–2234.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Hussain M, Vaishampayan U, Du W, Redman B, Smith DC . Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001; 19: 2527–2533.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We thank Pippa McKelvie-Sebileau and Jone Iriondo-Alberdi of Institut Bergonié for medical editorial.

Author information

Authors and Affiliations

  1. Primary Work, Institut Bergonie, Bordeaux, France

    P Sargos, L Ferretti, M Gross-Goupil, M Orre, F Cornelis, B Henriques de Figueiredo, N Houédé, C Merino, G Roubaud, B Dallaudiére, P Richaud & A Fléchon

Authors
  1. P Sargos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L Ferretti
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M Gross-Goupil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M Orre
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F Cornelis
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. B Henriques de Figueiredo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. N Houédé
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. C Merino
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. G Roubaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. B Dallaudiére
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. P Richaud
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. A Fléchon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to P Sargos.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Sargos, P., Ferretti, L., Gross-Goupil, M. et al. Characterization of prostate neuroendocrine cancers and therapeutic management: a literature review. Prostate Cancer Prostatic Dis 17, 220–226 (2014). https://doi.org/10.1038/pcan.2014.17

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/pcan.2014.17

This article is cited by

Search

Advanced search

Quick links